2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter

Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme; and an interview with Dr. Stacie Dusetzina - a leading researcher in health care policy and the cost of cancer drugs, and an avid Twitter user - of Vanderbilt University on #MedTwitter.

ECHELON-2: doi.org/10.1016/S0140-6736(18)32984-2
Facing Our Mistakes: doi.org/10.1056/NEJM198401123100211
Parachutes: doi.org/10.9778/cmajo.20170088
TTF: doi.org/10.1016/j.jcpo.2019.100189
Impact of Disclosing Financial Ties: doi.org/10.1001/archinternmed.2010.39

Back us on Patreon! www.patreon.com/plenarysession